Immix Biopharma Reports 2nd Interim Clinical Trial Data Readout In Relapsed/Refractory Metastatic Colorectal Cancer In Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Immix Biopharma, Inc. (NASDAQ:IMMX) has reported positive interim data from its ongoing Phase 1b/2a IMMINENT-01 clinical trial for IMX-110 in combination with BeiGene's anti-PD-1 antibody tislelizumab in patients with relapsed/refractory metastatic colorectal cancer. Tumor shrinkage was observed in 75% of patients and tumor control in 25% of patients. No severe adverse events were observed, allowing for the enrollment of the next higher dose cohort. The colorectal cancer market is estimated to reach approximately $31 billion by 2025.
July 17, 2023 | 1:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immix Biopharma's positive interim data from its ongoing Phase 1b/2a clinical trial for IMX-110 in colorectal cancer patients could potentially boost investor confidence and positively impact the company's stock price.
Positive clinical trial results often lead to increased investor confidence, which can result in a rise in the company's stock price. Given that the results are from an ongoing trial, the impact may be more significant as it indicates potential future success.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100